-
ABT-888 (Veliparib) for DNA Repair Workflows
2026-08-24
ABT-888 (Veliparib) enables controlled PARP1/2 inhibition for DNA repair inhibition, chemotherapy and radiation sensitization, and resistance studies. This practical guide connects colorectal cancer research and MSI tumor models with a newer biomarker-led strategy from high-grade serous ovarian cancer research.
-
BIRB 796 Workflows for p38α MAPK Research
2026-08-24
Build more interpretable p38α experiments with BIRB 796 (Doramapimod), from cytokine production inhibition and phospho-Western blots to apoptosis assays. This workflow combines selective allosteric inhibition with a recent dephosphorylation-focused model, helping researchers distinguish pathway suppression from changes in phospho-protein turnover.
-
ARCA Cy5 EGFP mRNA: Assay Guide
2026-08-23
ARCA Cy5 EGFP mRNA (5-moUTP) is a fluorescently labeled, 5-methoxyuridine modified mRNA for measuring delivery and EGFP expression in mammalian cells. Its paired Cy5 and EGFP readouts help separate intracellular cargo detection from translation, while the product record specifies a 996-nucleotide transcript supplied at 1 mg/mL.
-
ATRX Deficiency and RTK Inhibitor Sensitivity in Glioma
2026-08-22
The reference study identifies ATRX deficiency as a context associated with increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination results with temozolomide support ATRX-aware interpretation of targeted-treatment studies, while also emphasizing the need for validation in models that better reproduce tumor biology and drug exposure.
-
Topotecan in Recurrent Small Cell Lung Cancer
2026-08-21
This review established intravenous topotecan as a clinically useful option for recurrent small cell lung cancer (SCLC), including both chemosensitive and refractory relapse. Its key contribution was to connect efficacy, symptom palliation, dosing flexibility, and manageable hematologic toxicity in a treatment setting where prognosis and therapeutic choices were limited.
-
Caspase-3–NDUFS1 Signaling in Trichothecene Liver Injury
2026-08-20
This preprint identifies a caspase-3–NDUFS1 pathway that links trichothecene exposure to mitochondrial complex I disruption and amplified ROS production, while also implicating ER-localized ERO1α as a separate oxidative source. Its integrated mitochondrial–ER model helps explain hepatotoxicity mechanistically and suggests a framework for combining ROS, apoptosis, and membrane-potential measurements.
-
S-Adenosylhomocysteine in Neural Assays
2026-08-20
Use S-Adenosylhomocysteine to impose defined methyltransferase inhibition and test how SAM/SAH ratio modulation influences radiation-associated neural phenotypes. This workflow connects metabolic control with neurite outgrowth, neuronal marker expression, and pathway-focused validation while emphasizing careful dose, stability, and rescue controls.
-
Sex Differences in Angiotensin II Hypertension in Mice
2026-08-19
Xue, Pamidimukkala, and Hay used telemetry, gonadectomy, baroreflex testing, and ganglionic blockade to show that chronic angiotensin II produces substantially greater hypertension in male than female conscious mice. The study links this divergence to sex-dependent hormonal and autonomic mechanisms, providing a rigorous framework for interpreting cardiovascular experiments beyond resting blood pressure alone.
-
AZD2461: Reliable PARP Inhibitor Assays
2026-08-19
Learn how AZD2461 (SKU A4164) can support more interpretable viability, proliferation, and cytotoxicity experiments in breast cancer models. This scenario-based guide connects PARP biology with solvent handling, exposure design, endpoint selection, and vendor reliability.
-
Sulfamonomethoxine Workflows for Veterinary Research
2026-08-18
Sulfamonomethoxine (SMM) supports controlled susceptibility, veterinary microbiology, aquaculture, and environmental transformation studies without conflating laboratory activity with clinical dosing. This guide translates a veterinary staphylococcal testing strategy into practical assay design, stock preparation, comparative analysis, and troubleshooting.
-
IBDV VP3 Targets IRF7 to Evade Antiviral Defense
2026-08-18
A 2025 Frontiers study identifies IBDV VP3 as a viral antagonist of chicken IRF7, linking IRF7 depletion through the proteasome pathway to reduced IFN-β responses and enhanced viral replication. The work provides a mechanistic framework for studying how virulent IBDV strains manipulate host protein stability, while also defining important limits for translating proteostasis inhibitors into follow-up antiviral experiments.
-
1-Phenyl-2-Pentanol in Hepatic Fibrosis Research
2026-08-17
The reference study identifies 1-Phenyl-2-Pentanol from Moringa oleifera and evaluates its ability to suppress activation of human hepatic stellate cells in vitro. Its combined gene, protein, proteomic, and molecular-docking evidence connects reduced fibrosis markers with inhibition of TGF-β1- and Wnt/β-catenin-associated signaling, while also defining important limits for translational interpretation.
-
AptaBLE: Deep Learning for Aptamer Design
2026-08-17
AptaBLE combines pretrained protein and nucleic acid sequence encoders with symmetric bidirectional cross-attention to predict aptamer–protein binding and support de novo aptamer generation. The preprint reports improved predictive performance and generated candidates with reported Kd values as low as 31 nM, while also highlighting the need for experimental validation.
-
Roscovitine at the Cell Cycle–Immune Interface
2026-08-16
Roscovitine (Seliciclib, CYC202) offers translational researchers a way to interrogate how cyclin-dependent kinase control may intersect with radiotherapy and immune-checkpoint biology. This article separates established CDK pharmacology from forward-looking combination hypotheses, using a 2025 Cancer Letters study of radiotherapy with PD-1 and TIGIT blockade as an anchor for experimental strategy rather than as evidence of direct Roscovitine synergy.
-
EDTA-Free Protease Inhibitor for OXPHOS Assays
2026-08-15
A Protease Inhibitor Cocktail can protect the analytical validity of OXPHOS cancer studies, not merely improve protein yield. Learn how EDTA-free inhibition supports mechanistic interpretation across Western blotting, co-immunoprecipitation, kinase assays, and tissue extraction.